Download presentation
Presentation is loading. Please wait.
Published byKasey Ledwell Modified over 9 years ago
1
Complex Lesion Subsets: Indications for DES Andreas Baumbach, MD, FRCP, FESC Bristol Heart Institute
2
MY CONFLICTS OF INTEREST ARE Advisory Board Boston Scientific Advisory Board Abbott Vascular Educational Grants Cordis Educational Grants Boston Scientific
3
Complex Lesion Subsets What is complex ? What is a B2/C lesion ?
4
Type B2/C Lesions % of lesions Type B2/C Stent length
5
Lesion Complexity Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82:1193–1202
6
10-20mm length Eccentric Mod tortuosity Mod angulation 45-90º Irregular contour Mod/heavy calcification Ostial location Bifurcation requiring double wires Thrombus Total occlusion <3months Complex: B2/C >20mm length Excessive tortuosity Extremely angulated >90º Inability to protect major branch Degenerated vein graft Total occlusion > 3months BC
7
10-20mm length Eccentric Mod tortuosity Mod angulation 45-90º Irregular contour Mod/heavy calcification Ostial location Bifurcation requiring double wires Thrombus Total occlusion <3months Complex: B2/C >20mm length Excessive tortuosity Extremely angulated >90º Inability to protect major branch Degenerated vein graft Total occlusion > 3months BC
8
Complex Lesion Subsets Type B2/C Long Lesions Small Vessels CTO Vein Grafts Bifurcation Lesions LMS In-Stent Restenosis
9
Data Randomised Trial Randomised Trials Subgroup Analyses Published
10
Complexity in DES Trials multi-vessel disease bifurcated lesions ISR diabetes long lesions small vessels work -horse CTO left main disease TRIAL: randomized, multicenter, blinded, actively controlled trial involving an independent core lab and CEC TRIAL : feasibility studies involving only 1 to 3 centers often not using an independent core lab or CEC TAXUS V ISR SYNTAX TAXUS IV TAXUS V REALITY -TAXUS TAXUS VI SYNTAX TAXUS VI TAXUS V TAXUS IV TAXUS V REALITY -TAXUS Park LL2CORPAL-BIF SISR ISAR -DESIRE FREEDOM ISAR -DIABETES RIBS II RAVEL SES-SMART SIRIUS ISAR -SMART PRISON II REALITY -CYPHER DIABETES CARDIA Increasing complexity Data currently all 1 st generation DES
11
High Proportion of Type B2/C Lesions
12
Complex Lesions SCANDSTENT: Stenting in non-stress/benestent disease CTO (36%) /Bifurcation (34%)/Ostial (22%) /Angulated % N: 322, randomised Kelbaek et al. JACC 2006; 47:449 P<0.001 p<0.001 6 months outcome
13
Long Lesions
14
TAXUS VI : 3 yr Target Lesion Revascularisation
15
Long Lesions C-Sirius (Sirolimus eluting stent in the treatment of long de-novo lesions) Single de novo lesion 15-32mm length % N: 100, randomised C Sirius Investigators JACC 2004; 43: 1110 p<0.001 9 months outcome
16
Long Lesions E-Sirius (Sirolimus eluting stents for the treatment of patients with long atherosclerotic lesions in small coronary arteries) Single de novo lesion 15-32mm length, Vessel <3mm % N: 352, randomised Schofer et al. Lancet 2003; 362: 1093 p<0.001 p<0.0001 8 months outcome p<0.002
17
Small Vessels SES Smart Single lesion <2.75mm native coronary % N: 257, randomised Ardissino et al. JAMA 2004; 292: 2727 p<0.002 P<0.001 p<0.001 p<0.04 8 months outcome
18
Small Vessels
19
Chronic Total Occlusion PRISON II Single CTO >2 weeks, crossed and predilated % N: 200, randomised Suttorp et al. Circulation 2006;114:921 p<0.001 P<0.001 p<0.001 6 months outcome
20
Chronic Total Occlusion SCANDSTENT Subgroup analysis CTO, crossed and predilated % N: 127, randomised Kelbaek et al; Am Heart J 2006: 152:882 P<0.001 p<0.001 6 months outcome
21
Saphenous Vein Grafts RRISC Trial Lesions in SVG Grafts % N:75pts, 96 lesions, randomised Vermeersch et al JACC 2006; 48:2423 P=0.012 P=0.024 6 months outcome
22
Bifurcation Lesions SCANDSTENT subgroup Bifurcations: 126 pts randomised % Thuesen et al. Am Heart J 2006: 152:1140 P<0.001 6 months outcome P<0.001 p=0.01
23
Conclusion In the complex lesion subsets presented, use of DES significantly reduces the incidence of restenosis and the need for repeat revascularisation, when compared to bare metal stents
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.